ImmuPharma Major Opportunity Within Lupuzor Unlocked

ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas. Avion have a strong marketing and commercialisation operation (with over 100 specialist sales reps). Avion has exclusively in-licensed Lupuzor™ for the US market for Lupus (SLE) and other indications and agreed to fund an international Phase III clinical trial for up to US$25m. In addition, Avion will pay up to US$70m in milestones and a royalty stream tiered to 17% has been agreed. We have always believed that ImmuPharma could deliver such a successful deal for the US market (given the track record of the previous deal executed with Cephalon). This deal with Avion was aided by the strength of the clinical data (and safety profile) from the Phase III trial announced last year. Our detailed analysis of the respective cohort data, driven by the performance of the peptide in the auto ds-DNA antibody positive patients validated our assumptions of the value of Lupuzor™.

We now see Lupuzor™ as having the ability to generate blockbuster sales in the US (US$1bn+) alone (previously US and EU combined) – which when coupled with a royalty stream of up to 17% on revenues, could see an annual royalty to ImmuPharma’s bottom line of US$170m per year. What is particularly impressive about this deal is not only ImmuPharma’s ability to identify and execute a new licensing partner for Lupuzor™ but also the opportunity available for ImmuPharma to find new distribution and marketing partners outside the US for Lupuzor™, for e.g. in Europe, where a new trial would not even be required given Avion’s funding commitment. This means that there is a distinct possibility that further licensing deals could follow bringing in an attractive additional royalty stream, and additional upfront and milestone payments. Outside of Lupuzor™, we believe that ImmuPharma has the potential to generate news-flow on its other pipeline assets including Nucant and UreKa. Based on the financial assumptions for this deal, and a lower risk profile (reduction in risk premium in our DCF model) we increase our target price (which is 50% discounted) from 76p to 100p / share. BUY.

To read the full Life Sciences Division report, click here

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Pregnancy outcomes greatly improved in lupus patients

    Historically, pregnancy in patients with systemic lupus erythematosus (SLE) was considered so risky that physicians counseled women to avoid becoming pregnant and recommended that women carrying a child terminate their pregnancy. Now, a new study published

    Immupharma Plc

    Immupharma PLC Subscription to raise £2.66 million

    Commenting, ImmuPharma’s Chairman, Tim McCarthy, said: “We are delighted to be welcoming back Lanstead as a significant shareholder of the Company. Lanstead has been very supportive of the Company since their first investment in 2016 and

    Immupharma Plc

    10 Surprising Autoimmune Disease Facts You Need to Know

    If it seems like everyone and her grandma knows someone with an autoimmune disease, that’s because the term is a giant bucket that holds some 80 conditions, some as well-known as multiple sclerosis or type 1 diabetes, and as

    Immupharma Plc

    Autoimmune Diseases That Are Different For Women Than Men

    Research is just starting to explore how different conditions affect female-bodied people differently to male-bodied people. One of these areas in particular is in autoimmune conditions, where the immune system treats healthy tissues and cells as

    Immupharma Plc

    Why Autoimmune Diseases Cause the Body to Attack Itself

    A new study published in the journal Cell explores the cellular “runaway train” that allows lupus and other autoimmune diseases to spread throughout the body. Autoimmune disease is exactly what it sounds like—the body mistakenly fighting

    Immupharma Plc

    Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM)

    ImmuPharma’s Tim McCarthy discusses their final results, spend going forward, corporate strategy for Lupuzor, Nucant & Ureka, key milestones for shareholders and the initiation note issued by The Life Sciences Division in this exclusive interview with DirectorsTalk

    Immupharma Plc

    World Lupus Day: new report reveals need for care improvements

    The initiative is in collaboration with a Global Multidisciplinary Steering Committee, and the report outlines three specific, patient-centred Calls to Action to the lupus community. The report urges that we need increased awareness of lupus amongst